ARTICLE | Company News
BioMarin preparing for generic Kuvan suit
September 25, 2014 2:25 AM UTC
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said an undisclosed company submitted an ANDA to FDA for a generic version of BioMarin's Kuvan sapropterin dihydrochloride to treat phenylketonuria.
BioMarin said it has eight patents covering the drug, which expire between 2024 and 2026. BioMarin said it plans to file a patent infringement suit against the generic maker. ...